Skip navigation

Leadership Seminar – Immunotherapies: Hype, Hope and Reality

10:00 - 18:30

The Cambridge Building, Babraham Research Campus, Cambridge CB22 3AT
10 October 2017
Supported by:


Recent years have seen major advances in our understanding of complex disease mechanisms and the molecular engineering tools that allowed the concept of immunotherapy to become a reality. A range of biotechs emerged with a variety of therapeutic approaches raising interest in the investor and pharma communities as potential providers of breakthrough therapies tacking the 21st Century healthcare challenges.

It is now starting to deliver for patients with a recent example of the approval of Keytruda, but success must be balanced with the many challenges left whether regarding understanding of toxicity effects, drug delivery, patient segmentation, manufacturing and market access.

This Leadership Seminar will provide an overview of where the Immunotherapy field is currently with presentations from a variety of companies on their approaches in immune- oncology as still the dominant application but also other therapeutic areas. It will also discuss some of the challenges faced on the development pathway.

It should appeal to any academic or therapeutic company in the field of immunotherapies as well as anyone fascinated by this fast moving sector.


09.30 - Registration over Tea and Coffee

10.15 - Welcome

Scene Setting

10.25 - Overview of Industry Activity and Deals
Adrian Dawkes, PharmaVentures 

10.45 – New Approaches and Challenges in Immunotherapy
Robert Wilkinson, MedImmune

11.15 – Contribution of our understanding of the immune system in novel immunotherapy 
Stephen Bears, University of Southampton

11.45 - Title tbc

Camilo Colaço, immBio

12.15 - Lunch

13.35 - Innovative Approach to New Therapeutics in Immune-Oncology
This session will provide an overview of the different therapeutic approaches in immune-oncology, what differentiate them and where they can complement. It should include:

Speaker tbc

Neil Brewis, F-star

Andrew Mellor, Newcastle University 

Alice Brown
, Psioxus 

- Break

– Tackling Challenges on the Development Pathway 
This session will highlight the specific expertise needed in immunotherapies to allow an efficient translation of science, including:

Biomarker Validation
Alex Phipps
, Roche

Optimisation of Model Selection
Winfried Elis
, Charles River

Developing Preclinical Datapackage
Speaker tbc

17.00 - Closing Remarks and Drinks Reception

18.30 - Close 

Gold Members: £75 +VAT 
Silver Members: £175 +VAT 
Non-Members: £275 +VAT
Academics: £75 + VAT – please contact for your discount code.

Title: Leadership Seminar – Immunotherapies: Hype, Hope and Reality
Start: 2017-10-10 10:00:00Z
End: 2017-10-10 18:30:00Z